Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients-Reference-Cited by-同舟云学术

Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients

Published:2016-09-01 Issue:41 Volume:7 Page:67661-67673
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Liu Bo¹²,Ding Fengxia³²,Liu Yang¹²,Xiong Geng¹⁴,Lin Tao¹,He Dawei¹,Zhang Yuanyuan⁴,Zhang Deying¹²,Wei Guanghui¹

Affiliation:

1. Department of Urology, Children's Hospital of Chongqing Medical University, Chongqing, China

2. Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing International Science and Technology Cooperation Center for Child Development and Disorders, Chongqing, China

3. Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University, Chongqing, China

4. Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms, Clinical Management and Innovative Treatment;Drug Design, Development and Therapy;2024-09

2. Effect of Intensive Blood Pressure Control on Cardiovascular Outcomes in Cancer Survivors;Hypertension;2024-03

3. Cardiovascular adverse events in patients with hepatocellular carcinoma receiving vascular endothelial growth factor inhibitors;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2023-12-08

4. Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib;Drug Design, Development and Therapy;2023-11

5. Toxicity Management of Systemic Kidney Cancer Therapies;Hematology/Oncology Clinics of North America;2023-10